Pharma BD Deal Intelligence

Johnson & Johnson / Intra-Cellular Therapies, Inc.

2025 · Acquisition/Merger · $14.6B · Complete

J&J agreed to acquire Intra-Cellular Therapies for $132.00/share cash, total equity value ~$14.6B. Deal brings Caplyta, an oral antipsychotic approved for schizophrenia and bipolar depression, with pending sNDA for major depressive disorder. Announced at JPM 2025. Post-close validation: J&J completed the acquisition on April 2, 2025; the FDA approved Caplyta as adjunctive therapy for major depressive disorder in November 2025; and in Q1 2026 (reported April 14, 2026) Caplyta generated ~$270M in net sales with J&J reaffirming peak annual sales potential of greater than $5 billion.

Key facts

• Announced Jan 13, 2025
• Closed Apr 02, 2025
• Deal value $14.6B
• Deal type Acquisition/Merger
• Therapeutic area Schizophrenia, bipolar depression, major depressive disorder
• Indications Schizophrenia, bipolar depression, major depressive disorder
• Key assets Caplyta (lumateperone)
• Mechanism Serotonin-dopamine receptor modulator

← Browse all deals  ·  How we score deals